CG
MRSN

Cutler Group’s Mersana Therapeutics MRSN Stock Holding History

Cutler Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-48
Closed -$7.02K – 3952
2023
Q1 		$4K Hold
48
– – ﹤0.01% 2848
2022
Q4 		$7K Hold
48
– – ﹤0.01% 2951
2022
Q3 		$8K Hold
48
– – ﹤0.01% 3292
2022
Q2 		$5K Hold
48
– – ﹤0.01% 3729
2022
Q1 		$4K Hold
48
– – ﹤0.01% 4297
2021
Q4 		$7K Hold
48
– – ﹤0.01% 3961
2021
Q3 		$11K Sell
48
-184
-79% -$53.8K ﹤0.01% 3850
2021
Q2 		$78K Buy
232
+88
+61% +$33.3K ﹤0.01% 2089
2021
Q1 		$58K Buy
+144
New +$69.8K ﹤0.01% 2235
2020
Q4 		– Sell
-36
Closed -$20K – 5251
2020
Q3 		$16K Buy
+36
New +$18.2K ﹤0.01% 2643
2020
Q2 		– Sell
-8
Closed -$2.73K – 4688
2020
Q1 		$1K Buy
+8
New +$1.4K ﹤0.01% 3743

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Cutler Group's MRSN Position: Q2 2023 in Review

Cutler Group sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 48 shares — an estimated $7.02K sold.

Cutler Group first reported a position in MRSN in Q1 2020 and held it in 11 quarters. The position peaked at $78K in Q2 2021. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

  • Cutler Group reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Cutler Group sold 48 Mersana Therapeutics shares in Q2 2023, an estimated $7.02K.
  • Cutler Group first reported a position in Mersana Therapeutics in Q1 2020 and held it in 11 quarters.
  • Cutler Group's Mersana Therapeutics position peaked at $78K in Q2 2021.
  • 147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on Cutler Group's 13F filing for Q2 2023, filed 18 Jul 2023.